Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents

被引:192
作者
Pingaew, Ratchanok [1 ]
Saekee, Amporn [1 ]
Mandi, Prasit [2 ,3 ]
Nantasenamat, Chanin [2 ,3 ]
Prachayasittikul, Supaluk [2 ]
Ruchirawat, Somsak [4 ,5 ,6 ]
Prachayasittikul, Virapong [3 ]
机构
[1] Srinakharinwirot Univ, Dept Chem, Fac Sci, Bangkok 10110, Thailand
[2] Mahidol Univ, Fac Med Technol, Ctr Data Min & Biomed Informat, Bangkok 10700, Thailand
[3] Mahidol Univ, Fac Med Technol, Dept Clin Microbiol & Appl Technol, Bangkok 10700, Thailand
[4] Chulabhorn Res Inst, Bangkok 10210, Thailand
[5] Chulabhorn Grad Inst, Program Chem Biol, Bangkok 10210, Thailand
[6] Minist Educ, CHE, Ctr Excellence Environm Hlth & Toxicol EHT, Bangkok, Thailand
关键词
Chalcone; Coumarin; Triazole; Molecular docking; Cytotoxicity; Antimalarial activity; PLASMODIUM-FALCIPARUM; INHIBITORY-ACTIVITY; COLORIMETRIC ASSAY; DESIGN; GROWTH; DERIVATIVES; CHEMISTRY; INVITRO;
D O I
10.1016/j.ejmech.2014.07.087
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new series of chalcone coumarin derivatives (9-19) linked by the 1,2,3-triazole ring were synthesized through the azide/alkyne dipolar cycloaddition. Hybrid molecules were evaluated for their cytotoxic activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) and antimalarial activity toward Plasmodium falciparum. Most of the synthesized hybrids, except for analogs 10 and 16, displayed cytotoxicity against MOLT-3 cell line without affecting normal cells. Analogs (10, 11, 16 and 18) exhibited higher inhibitory efficacy than the control drug, etoposide, in HepG2 cells. Significantly, the high cytotoxic potency of the hybrid 11 was shown to be non-toxic to normal cells. Interestingly, the chalcone-coumarin 18 was the most potent antimalarial compound affording IC50 value of 1.60 mu M. Molecular docking suggested that the cytotoxicity of reported hybrids could be possibly due to their dual inhibition of alpha- and beta-tubulins at GTP and colchicine binding sites, respectively. Furthermore, falcipain-2 was identified to be a plausible target site of the hybrids given their antimalarial potency. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:65 / 76
页数:12
相关论文
共 61 条
[31]   Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer [J].
Lacy, A ;
O'Kennedy, R .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (30) :3797-3811
[32]   Conformationally restricted anti-plasmodial chalcones [J].
Larsen, M ;
Kromann, H ;
Kharazmi, A ;
Nielsen, SF .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4858-4861
[33]   In vitro antimalarial activity of chalcones and their derivatives [J].
Li, RS ;
Kenyon, GL ;
Cohen, FE ;
Chen, XW ;
Gong, BQ ;
Dominguez, JN ;
Davidson, E ;
Kurzban, G ;
Miller, RE ;
Nuzum, EO ;
Rosenthal, PJ ;
McKerrow, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (26) :5031-5037
[34]   Antimalarial alkoxylated and hydroxylated chalones: Structure-activity relationship analysis [J].
Liu, M ;
Wilairat, P ;
Go, ML .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4443-4452
[35]   AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility [J].
Morris, Garrett M. ;
Huey, Ruth ;
Lindstrom, William ;
Sanner, Michel F. ;
Belew, Richard K. ;
Goodsell, David S. ;
Olson, Arthur J. .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2009, 30 (16) :2785-2791
[37]   Design, synthesis and anticancer activity of nitric oxide donating/chalcone hybrids [J].
Mourad, Mai A. E. ;
Abdel-Aziz, Mohamed ;
Abuo-Rahma, Gamal El-Din A. A. ;
Farag, Hassan H. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 54 :907-913
[38]   Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design [J].
Muregi, Francis W. ;
Ishih, Akira .
DRUG DEVELOPMENT RESEARCH, 2010, 71 (01) :20-32
[39]   Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids [J].
Nepali, Kunal ;
Sharma, Sahil ;
Sharma, Manmohan ;
Bedi, P. M. S. ;
Dhar, K. L. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 77 :422-487
[40]   Recent advances in therapeutic chalcones [J].
Ni, LM ;
Meng, CQ ;
Sikorski, JA .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (12) :1669-1691